UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 73

Sortiert nach

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

Annals of oncology, 2013-12, Vol.24 (12), p.2978-2984

2013

Link zum Volltext

Verfügbarkeit prüfen

Early prediction of pathologic response to neoadjuvant therapy in breast cancer: Systematic review of the accuracy of MRI

Breast (Edinburgh), 2012-10, Vol.21 (5), p.669-677

2012

Link zum Volltext

Verfügbarkeit prüfen

Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro)

Annals of oncology, 2014-01, Vol.25 (1), p.81-89

2014

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer

Annals of oncology, 2013-09, Vol.24 (9), p.2316-2324

2013

Link zum Volltext

Verfügbarkeit prüfen

Optimizing taxane use in MBC in the emerging era of targeted chemotherapy

Critical reviews in oncology/hematology, 2013-03, Vol.85 (3), p.315-331

2013

Link zum Volltext

Verfügbarkeit prüfen

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

Annals of oncology, 2013-02, Vol.24 (2), p.398-405

2013

Link zum Volltext

Verfügbarkeit prüfen

Prognostische Bedeutung des Tumorzellnachweises im Knochenmark im Vergleich zum Nodalstatus beim primären Mammakarzinom

Geburtshilfe und Frauenheilkunde, 1997-06, Vol.57 (6), p.333-341

1997

Link zum Volltext

Verfügbarkeit prüfen

PG 8.03 Clinical usefulness and relevance of intermediate endpoints for cytotoxic primary systemic therapy

Breast (Edinburgh), 2015-03, Vol.24, p.S14-S15

Von Minckwitz, G

2015

Link zum Volltext

Verfügbarkeit prüfen

Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)

European journal of cancer (1990), 2016-09, Vol.64, p.12-21

2016

Link zum Volltext

Verfügbarkeit prüfen

Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis

European journal of cancer (1990), 2009-03, Vol.45 (4), p.608-617

2009

Link zum Volltext

Verfügbarkeit prüfen

RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy

Annals of oncology, 2013-03, Vol.24 (3), p.632-639

2013

Link zum Volltext

Verfügbarkeit prüfen

First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial

European journal of cancer (1990), 2010-12, Vol.46 (18), p.3184-3191

2010

Link zum Volltext

Verfügbarkeit prüfen

1801 Neoadjuvant chemotherapy with trastuzumab or lapatinib: Survival analysis of the HER2-positive cohort of the GeparQuinto study (GBG 44)

European journal of cancer (1990), 2015-09, Vol.51, p.S264-S264

2015

Link zum Volltext

Verfügbarkeit prüfen

Present and future breast cancer management—bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry

Annals of oncology, 2014-04, Vol.25 (4), p.773-780

2014

Link zum Volltext

Verfügbarkeit prüfen

IIIB.3 Breast cancer: from old to new taxanes?

Critical reviews in oncology/hematology, 2007-11, Vol.64, p.S15-S15

von Minckwitz, G

2007

Link zum Volltext

Verfügbarkeit prüfen

40 Patient Self-reported Outcome for Long-term Follow up of Early Breast Cancer Trials

European journal of cancer (1990), 2012-03, Vol.48, p.S52-S52

2012

Link zum Volltext

Verfügbarkeit prüfen

Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response

Breast (Edinburgh), 2007-02, Vol.16 (1), p.86-93

2007

Link zum Volltext

Verfügbarkeit prüfen

Ein Kommentar zur klinischen Forschung in Deutschland am Beispiel der gynäkologischen Onkologie - Wege aus einer Sackgasse

Geburtshilfe und Frauenheilkunde, 1998-03, Vol.58 (3), p.133-138

1998

Link zum Volltext

Verfügbarkeit prüfen

11 Everolimus (Rad001) as Treatment in Breast Cancer Patients with Bone Metastases Only – First Results of the Multi-centre, Placebo-controlled, Randomized Discontinuation Phase II RADAR Study

European journal of cancer (1990), 2012-03, Vol.48, p.S43-S43

2012

Link zum Volltext

Verfügbarkeit prüfen

138 Anti-HER2 therapy treatment after progression

European journal of cancer supplements, 2009, Vol.7 (2), p.34-35

von Minckwitz, G

2009

Link zum Volltext

Verfügbarkeit prüfen

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials

The Lancet (British edition), 2014-06, Vol.383 (9935), p.2127-2135

2014

Link zum Volltext

Verfügbarkeit prüfen

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

The Lancet (British edition), 2015-10, Vol.386 (10001), p.1341-1352

Anon

2015

Link zum Volltext

Verfügbarkeit prüfen

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

Annals of oncology, 2014-12, Vol.25 (12), p.2363-2372

2014

Link zum Volltext

Verfügbarkeit prüfen

5067 Increased overall response rate to capecitabine in different patient subgroups: results of an open-label phase II study in pretreated metastatic breast cancer

European journal of cancer supplements, 2009, Vol.7 (2), p.280-280

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 73

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Zeitschrift / SerieOnkologie

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(71)

Publikationsform

Artikel
(69)
Tagungsberichte
(4)

Sprache

Erscheinungsjahr

n.n

Thema

Hematology, Oncology And Palliative Medicine
(42)
Science & Technology
(24)
Life Sciences & Biomedicine
(23)
Humans
(22)
Female
(21)
Oncology
(20)
Breast Neoplasms - Drug Therapy
(18)
Middle Aged
(15)
Adult
(13)
Biological And Medical Sciences
(13)
Breast Cancer
(13)
Medical Sciences
(13)
Tumors
(13)
Aged
(10)
Pharmacology. Drug Treatments
(10)
Gynecology. Andrology. Obstetrics
(9)
Mammary Gland Diseases
(9)
Treatment Outcome
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Breast Neoplasms - Mortality
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

Early prediction of pathologic response to neoadjuvant therapy in breast cancer: Systematic review of the accuracy of MRI

Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro)

Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer

Optimizing taxane use in MBC in the emerging era of targeted chemotherapy

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

Prognostische Bedeutung des Tumorzellnachweises im Knochenmark im Vergleich zum Nodalstatus beim primären Mammakarzinom

PG 8.03 Clinical usefulness and relevance of intermediate endpoints for cytotoxic primary systemic therapy

Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC

Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)

Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis

RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy

First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial

1801 Neoadjuvant chemotherapy with trastuzumab or lapatinib: Survival analysis of the HER2-positive cohort of the GeparQuinto study (GBG 44)

Present and future breast cancer management—bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry

IIIB.3 Breast cancer: from old to new taxanes?

40 Patient Self-reported Outcome for Long-term Follow up of Early Breast Cancer Trials

Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response

Ein Kommentar zur klinischen Forschung in Deutschland am Beispiel der gynäkologischen Onkologie - Wege aus einer Sackgasse

11 Everolimus (Rad001) as Treatment in Breast Cancer Patients with Bone Metastases Only – First Results of the Multi-centre, Placebo-controlled, Randomized Discontinuation Phase II RADAR Study

138 Anti-HER2 therapy treatment after progression

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

5067 Increased overall response rate to capecitabine in different patient subgroups: results of an open-label phase II study in pretreated metastatic breast cancer

Aktive Filter

Suchergebnisse filtern